1. Home
  2. VRRM vs MESO Comparison

VRRM vs MESO Comparison

Compare VRRM & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verra Mobility Corporation

VRRM

Verra Mobility Corporation

HOLD

Current Price

$16.59

Market Cap

2.7B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.11

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRRM
MESO
Founded
1987
2004
Country
United States
Australia
Employees
N/A
81
Industry
Transportation Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.2B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
VRRM
MESO
Price
$16.59
$14.11
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$26.90
N/A
AVG Volume (30 Days)
1.8M
199.0K
Earning Date
05-26-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
347.37
N/A
EPS
0.85
N/A
Revenue
$132,969,000.00
N/A
Revenue This Year
$6.63
$633.98
Revenue Next Year
$7.66
$29.51
P/E Ratio
$19.76
N/A
Revenue Growth
14.61
N/A
52 Week Low
$15.58
$9.61
52 Week High
$25.83
$21.50

Technical Indicators

Market Signals
Indicator
VRRM
MESO
Relative Strength Index (RSI) 30.25 30.02
Support Level N/A $10.14
Resistance Level $25.18 $16.32
Average True Range (ATR) 0.63 0.50
MACD -0.08 -0.24
Stochastic Oscillator 28.09 15.60

Price Performance

Historical Comparison
VRRM
MESO

About VRRM Verra Mobility Corporation

Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe, and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three reportable segments: Commercial Services, Government Solutions, and Parking Solutions. Maximum revenue is generated from the Commercial Services segment, which offers toll and violation management solutions and title and registration services for commercial fleet customers, including RACs and FMCs in North America. In Europe, it provides tolling and violations processing services.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: